19 The clinical impact of a novel nurse-led secondary prevention lipid service

<h3>Background</h3> Hyperlipidaemia is responsible for 25% of cardiovascular deaths (NHS England 2019). Despite this, the Cardiovascular Disease Prevention Audit (CVDPREVENT) and local data have shown that lipid-lowering therapy in Dorset is in the lowest quartile nationally. Consequently, a nurse-led secondary CVD prevention service was set up to improve lipid-lowering performance in East Dorset. Its one-year performance data is presented and compared to the preceding year prior to service commencement. <h3>Methods</h3> The service started in July 2023 and supported by a two-year ring-fenced industry grant. All patients hospitalised with an acute coronary syndrome or requiring revascularisation for flow limiting coronary artery disease and a serum LDL-cholesterol (LDL-C) &gt;2.0 mmol/L were included. An advanced nurse practitioner-led face-to-face consultation was undertaken at three months post index hospitalisation, followed by further telephone consultations at six and twelve months respectively. Fasting venous blood lipids were measured at each visit with signposting to ancillary services (eg smoking prevention and weight reduction), where indicated. The treatment target was an LDL-C &lt;2.0mmol/l (NICE 2023).<sup>3</sup> Treatment effect was measured using Chi-square and ANOVA testing for categorical and continuous data respectively. <h3>Results</h3> East Dorset MINAP data from 2022 has shown that 1058/2268(46.6%) of patients achieved an LDL-C &lt;2.0mmol/l. Data from the first 177 consecutive patients (one-year) of the new service (mean age 66.34±10.72 years; 65.5% men) showed that LDL-C was 3.16±1.27 mmol/l at hospital admission, 2.20±0.89mmol/l at 3 months (baseline visit), 1.74±0.67mmol/l at 6 months and 1.68±0.60mmol/l at 12 months (p&lt;0.0001). An LDL-C of &lt;2.0 mmol/l was achieved in 42.7% at three months, 75% at six months and 78.8% at twelve months (p&lt;0.0001). Twenty-one patients were commenced on injectable lipid modification therapy. <h3>Conclusions</h3> The introduction of a nurse-led secondary prevention service has led to marked improvements in lipid lowering performance in East Dorset and needs to be expanded.

Authors

Institutions

Publication Details

Published
2024-09-30
DOI
https://doi.org/10.1136/heartjnl-2024-bacpr.19
Primary Topic
Health Promotion and Cardiovascular Prevention
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

19 The clinical impact of a novel nurse-led secondary prevention lipid service

Anthony Young, Christopher John Boos, Alice Bendea, Rajan Pooni
Health Promotion and Cardiovascular Prevention
article

19 The clinical impact of a novel nurse-led secondary prevention lipid service

Anthony Young, Christopher John Boos, Alice Bendea, Rajan Pooni
article en

Abstract

<h3>Background</h3> Hyperlipidaemia is responsible for 25% of cardiovascular deaths (NHS England 2019). Despite this, the Cardiovascular Disease Prevention Audit (CVDPREVENT) and local data have shown that lipid-lowering therapy in Dorset is in the lowest quartile nationally. Consequently, a nurse-led secondary CVD prevention service was set up to improve lipid-lowering performance in East Dorset. Its one-year performance data is presented and compared to the preceding year prior to service commencement. <h3>Methods</h3> The service started in July 2023 and supported by a two-year ring-fenced industry grant. All patients hospitalised with an acute coronary syndrome or requiring revascularisation for flow limiting coronary artery disease and a serum LDL-cholesterol (LDL-C) &gt;2.0 mmol/L were included. An advanced nurse practitioner-led face-to-face consultation was undertaken at three months post index hospitalisation, followed by further telephone consultations at six and twelve months respectively. Fasting venous blood lipids were measured at each visit with signposting to ancillary services (eg smoking prevention and weight reduction), where indicated. The treatment target was an LDL-C &lt;2.0mmol/l (NICE 2023).<sup>3</sup> Treatment effect was measured using Chi-square and ANOVA testing for categorical and continuous data respectively. <h3>Results</h3> East Dorset MINAP data from 2022 has shown that 1058/2268(46.6%) of patients achieved an LDL-C &lt;2.0mmol/l. Data from the first 177 consecutive patients (one-year) of the new service (mean age 66.34±10.72 years; 65.5% men) showed that LDL-C was 3.16±1.27 mmol/l at hospital admission, 2.20±0.89mmol/l at 3 months (baseline visit), 1.74±0.67mmol/l at 6 months and 1.68±0.60mmol/l at 12 months (p&lt;0.0001). An LDL-C of &lt;2.0 mmol/l was achieved in 42.7% at three months, 75% at six months and 78.8% at twelve months (p&lt;0.0001). Twenty-one patients were commenced on injectable lipid modification therapy. <h3>Conclusions</h3> The introduction of a nurse-led secondary prevention service has led to marked improvements in lipid lowering performance in East Dorset and needs to be expanded.

Poole Hospital (GB)
Openalex Percentile: Top 75%
Health Promotion and Cardiovascular Prevention
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

19 The clinical impact of a novel nurse-led secondary prevention lipid service — Anthony Young, Christopher John Boos, et al. · (2024) | TGRS Research Map | TGRS